BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.
| Revenue (Most Recent Fiscal Year) | $0.64M |
| Net Income (Most Recent Fiscal Year) | $-69.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.11 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -9549.87% |
| Net Margin (Trailing 12 Months) | -9549.87% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -185.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 0.64 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-4.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.49 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.79 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 31.31M |
| Free Float | 30.15M |
| Market Capitalization | $1.57M |
| Average Volume (Last 20 Days) | 17.51M |
| Beta (Past 60 Months) | 0.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 30.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |